Skip navigation.

Supply Planning for New Dosage Form of Lopinavir and Ritonavir Oral Pellets

Publication year: 
Corporate author: 
Publication details: 
Geneva, WHO, 2015

This policy brief provides antiretroviral therapy (ART) programme managers, implementing partners, procurement and supply chain managers, and other relevant stakeholders with key points to consider before and during the introduction of the new dosage form of ritonavir-boosted lopinavir (LPV/r) oral pellets. The pellets are packaged into capsules with each capsule containing the equivalent of 40mg of LPV and 10mg of ritonavir. The LPV/r pellet1 dosage form can be sprinkled on soft food or given with breastmilk or formula. It is hoped that the new dosage form will address some of the long standing challenges presented by use of the currently available paediatric dosage forms of LPV/r.2

For countries deciding to include LPV/r pellets in their national guidelines for the treatment of HIV-infected infants and young children, it is important to take a coordinated approach to the introduction of this product in order to support a reliable supply chain with timely and appropriate uptake at the patient-level.

The information contained herein does not replace that provided with the product, as approved by the regulatory authority. Practitioners are encouraged to read the approved product package insert and relevant treatment guidelines for more detailed and up-to-date information